Last checked at 
(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.
The AIM-traded firm said the work was completed as part of the pan-European CANCER-ID consortium, funded by the European Innovative Medicine Initiative (IMI), which aimed to standardise protocols and validate innovative circulating tumour cell (CTC) detection approaches for future clinical trials.
It said the results demonstrated the capability of the Parsortix system to work with multiple different cancer types, using multiple blood preservative tube types, and capturing the full range of CTCs, not just epithelial CTCs.
The researchers reportedly demonstrated that the CTCs harvested by the Parsortix system were suitable for "robust amplification of single cell DNA at excellent quality for subsequent molecular analysis".
It said that, even in metastatic non-small cell lung cancer (NSCLC) and gastrointestinal cancer, which were known to be problematic for CTC enrichment, the Parsortix workflow harvested CTCs in 46% of patients notwithstanding treatment and disease condition.
The researchers stated in the publication that they had established optimised enrichment protocols, utilising Parsortix, which apparently ensured "robust" performance.
Angle said the research had been published as a peer-reviewed publication in the journal Cancers.
"This publication adds to the body of evidence supporting the use of Parsortix in standard practice as part of personalised cancer care," said founder and chief executive Andrew Newland.
"Hamburg-Eppendorf is considered a leader in Europe in the field and their positive evaluation of Parsortix is an important element in supporting the potential use of Parsortix in future pharma services clinical trials."
As it had previously announced, following the Q-submission meeting in January with US Food and Drug Administration (FDA), Angle was now progressing a full De Novo FDA submission with the prospect of clearance in the third quarter of 2020.
It noted that the outcome and timing of the FDA regulatory decision was "entirely dependent" on the administration's review and response to its submission.
At 1523 GMT, shares in Angle were flat at 72.5p.
14 Jun 2022 20:13
IN BRIEF: Angle's Parsortix performs well on prostate cancer patients
Angle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says.
Read more